miltefosine has been researched along with African Sleeping Sickness in 8 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This work describes the optimization of the pharmacokinetic properties of a previously published family of triazine lead compounds." | 1.48 | Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives. ( Augustyns, K; Baán, A; Caljon, G; Kiekens, F; Maes, L; Matheeussen, A; Salado, IG; Van der Veken, P; Verdeyen, T, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrins, L | 1 |
| Rahmani, R | 1 |
| Sykes, ML | 1 |
| Jones, AJ | 1 |
| Avery, VM | 1 |
| Teston, E | 1 |
| Almohaywi, B | 1 |
| Yin, J | 1 |
| Smith, J | 1 |
| Hyland, C | 1 |
| White, KL | 1 |
| Ryan, E | 1 |
| Campbell, M | 1 |
| Charman, SA | 1 |
| Kaiser, M | 3 |
| Baell, JB | 1 |
| Papadopoulou, MV | 1 |
| Bloomer, WD | 1 |
| Rosenzweig, HS | 1 |
| Wilkinson, SR | 1 |
| Szular, J | 1 |
| Jagu, E | 1 |
| Pomel, S | 1 |
| Diez-Martinez, A | 1 |
| Ramiandrasoa, F | 1 |
| Krauth-Siegel, RL | 1 |
| Pethe, S | 1 |
| Blonski, C | 1 |
| Labruère, R | 1 |
| Loiseau, PM | 2 |
| Salado, IG | 1 |
| Baán, A | 1 |
| Verdeyen, T | 1 |
| Matheeussen, A | 1 |
| Caljon, G | 1 |
| Van der Veken, P | 1 |
| Kiekens, F | 1 |
| Maes, L | 1 |
| Augustyns, K | 1 |
| Saccoliti, F | 1 |
| Madia, VN | 1 |
| Tudino, V | 1 |
| De Leo, A | 1 |
| Pescatori, L | 1 |
| Messore, A | 1 |
| De Vita, D | 1 |
| Scipione, L | 1 |
| Brun, R | 2 |
| Mäser, P | 1 |
| Calvet, CM | 1 |
| Jennings, GK | 1 |
| Podust, LM | 1 |
| Costi, R | 1 |
| Di Santo, R | 1 |
| Papagiannaros, A | 1 |
| Bories, C | 1 |
| Demetzos, C | 1 |
| Croft, SL | 1 |
| Snowdon, D | 1 |
| Yardley, V | 1 |
| Konstantinov, SM | 1 |
| Kaminsky, R | 1 |
| Berger, MR | 1 |
| Zillmann, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
8 other studies available for miltefosine and African Sleeping Sickness
| Article | Year |
|---|---|
3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
Topics: Anilides; Animals; Humans; Mice; Myoblasts, Skeletal; Rats; Species Specificity; Structure-Activity | 2013 |
Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.
Topics: Acetamides; Animals; Mice; Nitroreductases; Structure-Activity Relationship; Triazoles; Trypanocidal | 2016 |
Synthesis and in vitro antikinetoplastid activity of polyamine-hydroxybenzotriazole conjugates.
Topics: Animals; Antiprotozoal Agents; Humans; Leishmania donovani; Leishmaniasis, Visceral; NADH, NADPH Oxi | 2017 |
Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives.
Topics: Animals; Disease Models, Animal; Humans; Mice; Structure-Activity Relationship; Triazines; Tropolone | 2018 |
Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents.
Topics: Animals; Antiprotozoal Agents; Cell Line; Chagas Disease; Female; Humans; Imidazoles; Inhibitory Con | 2018 |
Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.
Topics: Amines; Animals; Chemistry, Pharmaceutical; Disease Models, Animal; Dose-Response Relationship, Drug | 2005 |
The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.
Topics: Animals; Antineoplastic Agents; Chagas Disease; Cricetinae; Female; Furans; Leishmania donovani; Lei | 1996 |
Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Drug Synergism; Drug Therap | 1997 |